{"id":550241,"date":"2021-06-29T14:38:01","date_gmt":"2021-06-29T14:38:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=550241"},"modified":"2021-06-29T14:38:01","modified_gmt":"2021-06-29T14:38:01","slug":"cholangiocarcinoma-market-dynamic-demand-and-drives-with-forecast-to-2030-delcath-systems-inc-imbrium-therapeutics-lp","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cholangiocarcinoma-market-dynamic-demand-and-drives-with-forecast-to-2030-delcath-systems-inc-imbrium-therapeutics-lp_550241.html","title":{"rendered":"Cholangiocarcinoma Market Dynamic Demand and Drives with Forecast to 2030 | Delcath Systems Inc., Imbrium Therapeutics L.P."},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1624947707.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Cholangiocarcinoma Market Dynamic Demand and Drives with Forecast to 2030 | Delcath Systems Inc., Imbrium Therapeutics L.P.\" src=\"https:\/\/www.abnewswire.com\/uploads\/1624947707.jpeg\" alt=\"Cholangiocarcinoma Market Dynamic Demand and Drives with Forecast to 2030 | Delcath Systems Inc., Imbrium Therapeutics L.P.\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The global cholangiocarcinoma market is classified on the basis of treatment type, distribution channel, and region. In terms of region, the market is divided into chemotherapy, targeted therapy, and immunotherapy. A<\/div>\n<p style=\"text-align: justify;\"><strong>Cholangiocarcinoma Market: Overview<\/strong><\/p>\n<p><span>Cholangiocarcinoma is a type of cancer forming in the bile ducts inside the stomach that carries the digestive fluid bile. Bile ducts link our liver on our gallbladder and in the small gut. This condition, also known as bile duct cancer, is an unusual form of most cancers that occurs typically in humans older than 50 years of age, even though it can happen at any age. The rising number of digestive issues among the aged population is considered a prime factor augmenting the growth of this market during the forecast period, 2020 to 2030.<\/span><\/p>\n<div class=\"d-print-none\" style=\"text-align: justify;\"><strong>&nbsp;<\/strong><span data-mce-mark=\"1\"><strong>Get Exclusive PDF Sample Copy Of This Report:<\/strong>&nbsp;<\/span><a rel=\"nofollow\" href=\"https:\/\/www.tmrresearch.com\/sample\/sample?flag=B&amp;rep_id=7484\" target=\"_blank\"><span data-mce-mark=\"1\">https:\/\/www.tmrresearch.com\/sample\/sample?flag=B&amp;rep_id=7484<\/span><\/a><\/div>\n<p style=\"text-align: justify;\"><span data-mce-mark=\"1\">The global cholangiocarcinoma market is classified on the basis of treatment type, distribution channel, and region. In terms of region, the market is divided into chemotherapy, targeted therapy, and immunotherapy. Among these, the chemotherapy is further segmented into 5 fluorouracil, capecitabine, oxaliplatin, cisplatin, and gemcitabine. The targeted therapy segment is further classified into ivosidenib, infigratinib, and pemigatinib. The immunotherapy segment is again categorized into pembrolizumab, and others. With respect to segmentation by distribution channel, the global market for cholangiocarcinoma is divided into retail pharmaceies, hospital pharmacies, and online pharmacies.<\/span><\/p>\n<p><span data-mce-mark=\"1\">The report is based on qualitative and quantitative analysis of the market and its prime growth trajectories including the recent trends and innovations along with restraints and drivers. It also throws light on the impact of the novel Coronavirus on this market and what measures can be adopted to help this market continue earning handsome revenues at the time of a worldwide pandemic. Furthermore, the report emphasizes on the table of segmentation and mentions the leading segment with factors attributing to its growth. The report is available for sale on the company website.<\/span><\/p>\n<p><strong>Cholangiocarcinoma Market: Company Profiles<\/strong><\/p>\n<p><span data-mce-mark=\"1\">Major manufacturers of the global cholangiocarcinoma market are indulging in strategic collaborations to gain an upper hand in the overall market competition. Apart from this, some other players are investing in research and development of better therapeutics to treat various cancer types especially cancer of the bile duct.<\/span><\/p>\n<p><strong>Some of the notable players of the global cholangiocarcinoma market include:<\/strong><\/p>\n<p><span data-mce-mark=\"1\">Delcath Systems Inc.<\/span><br \/><span data-mce-mark=\"1\">Imbrium Therapeutics L.P.<\/span><br \/><span data-mce-mark=\"1\">Incyte Corporation<\/span><br \/><span data-mce-mark=\"1\">Ability Pharmaceuticals<\/span><br \/><span data-mce-mark=\"1\">RenovoRx,<\/span><br \/><span data-mce-mark=\"1\">Agios Pharmaceuticals, Inc.<\/span><br \/><span data-mce-mark=\"1\">QED Therapeutics, Inc.<\/span><br \/><span data-mce-mark=\"1\">Eisai Co., Ltd.<\/span><\/p>\n<p style=\"text-align: justify;\"><span><strong>Buy This Report @<\/strong>&nbsp;<\/span><span class=\"intext-a opr-li click-to-go-x\" data-url=\"https:\/\/opr.li\/com\/63912aca6827c16f146fa24d7c8f2de9\/\">https:\/\/www.tmrresearch.com\/checkout?rep_id=7484<\/span><\/p>\n<p><strong>About TMR Research<\/strong><\/p>\n<p><span>TMR Research is a premier provider of customized market research and consulting services to busi-ness entities keen on succeeding in today&rsquo;s supercharged economic climate. Armed with an experi-enced, dedicated, and dynamic team of analysts, we are redefining the way our clients&rsquo; conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.<\/span><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/tmrresearch.com_25319.html\" rel=\"nofollow\">TMR Research<\/a><br \/><strong>Contact Person:<\/strong> Rohit Bhisey<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=cholangiocarcinoma-market-dynamic-demand-and-drives-with-forecast-to-2030-delcath-systems-inc-imbrium-therapeutics-lp\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +1-415-520-1050<br \/><strong>City:<\/strong> San Francisco<br \/><strong>State:<\/strong> CA<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.tmrresearch.com\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.tmrresearch.com<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.tmrresearch.com\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=cholangiocarcinoma-market-dynamic-demand-and-drives-with-forecast-to-2030-delcath-systems-inc-imbrium-therapeutics-lp\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The global cholangiocarcinoma market is classified on the basis of treatment type, distribution channel, and region. In terms of region, the market is divided into chemotherapy, targeted therapy, and immunotherapy. A Cholangiocarcinoma Market: Overview Cholangiocarcinoma is a type of cancer &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/cholangiocarcinoma-market-dynamic-demand-and-drives-with-forecast-to-2030-delcath-systems-inc-imbrium-therapeutics-lp_550241.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406],"tags":[],"class_list":["post-550241","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/550241","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=550241"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/550241\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=550241"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=550241"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=550241"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}